nAChR-Targeting Polypeptide with Disulfide Bonds for Receptor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches lack effective compounds that can specifically target nicotinic acetylcholine receptors (nAChRs) for the treatment of diseases such as muscle weakness, epilepsy, neurodegenerative diseases, mental illnesses, and nicotine addiction, necessitating the development of novel targeting molecules.
Innovation Solution
A novel polypeptide, nAChR_BP, with a specific amino acid sequence forming disulfide bonds, is designed to target and inhibit nAChR subunits, forming a stable complex and inhibiting receptor activity, which is synthesized and tested for therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug development approaches are used, then general therapeutic effects can be achieved, but specific targeting capacity for nAChR is insufficient
Solution Approach 1:
The polypeptide incorporates specific amino acid sequences with localized binding properties that specifically recognize and bind to nAChR subunits. This local quality enhancement allows the molecule to achieve high specificity for nAChR targets while maintaining the ability to address multiple nAChR-related diseases through the same specific binding mechanism.
2Reliability
If polypeptides with high specific targeting capacity are designed, then binding specificity to nAChR improves, but structural stability may be compromised
Solution Approach 1:
The polypeptide employs a composite structural design combining multiple amino acid residues with specific binding properties. This composite structure includes strategically positioned cysteine residues that form disulfide bonds, creating a stable three-dimensional configuration that maintains both high binding specificity for nAChR and structural stability in physiological conditions.
Solution Approach 2:
The design optimizes specific parameters including the positioning of cysteine residues to form disulfide bonds at defined distances, controlling the three-dimensional structure. This parameter optimization ensures the polypeptide maintains structural stability while preserving the specific binding interface for nAChR recognition.
3Reliability
If novel polypeptide structures are designed for specific nAChR targeting, then therapeutic potential improves, but development complexity increases
Solution Approach 1:
The polypeptide is designed as a segmented structure with distinct functional regions: N-terminal and C-terminal domains with specific amino acid sequences for nAChR binding, and intermediate cysteine residues for structural stabilization. This segmentation allows systematic design and optimization of binding specificity while managing structural complexity through modular organization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively inhibits nAChR activity, demonstrating potential as a therapeutic agent for treating nAChR-related diseases by significantly reducing calcium response in nAChR-overexpressing cells, offering a promising drug candidate with broad application prospects.
Implementation Method 1
The polypeptide comprises four cysteine residues, Cys2, Cys3, Cys7, and Cys13, that can form two disulfide bonds
Implementation Method 2
Molecular docking simulation illustrated its capacity to target α and α7 subunits of nAChR and the stable structure of resultant nAChR_BP-nAChR complex
Implementation Method 3
effect of the polypeptide on calcium response of nAChR-overexpressing CN21 cells revealed that the polypeptide was capable of significantly inhibiting nAChRs
Data Source
AI summary
A neuronal nicotinic acetylcholine receptor-targeting polypeptide and the use thereof are disclosed. The polypeptide has an amino acid sequence of SEQ ID NO:1, and includes four cysteine residues, Cys2, Cys3, Cys7, and Cys13, that can form two disulfide bonds. Molecular docking simulation illustrated its capacity to target a and a subunits of nAChR and the stable structure of resultant nAChR_BP-nAChR complex. In addition, effect of the polypeptide on calcium response of nAChR-overexpressing CN21 cells revealed that the polypeptide was capable of significantly inhibiting nAChRs. Accordingly, the nAChR-targeting polypeptide nAChR_BP is a promising nAChR-targeting drug.